Even After a Big Run, This Biotech Pick Has Ample Upside
Posted on August 20, 2012 at 18:30 PM EDT
For readers who have not been following our newsletter editors for an extended period, it's time to acquaint you with a longstanding policy: We never buy a stock for one of our portfolios . . . → Read More: Even After a Big Run, This Biotech Pick Has Ample Upside

Even After a Big Run, This Biotech Pick Has Ample Upside

For readers who have not been following our newsletter editors for an extended period, it's time to acquaint you with a longstanding policy: We never buy a stock for one of our portfolios for 2 trading days after you read about it. This means we'll never front-run a stock, getting in before the crowd as many "pump and dump" financial advisory firms do. It also means we hamstring … [visit site to read more]

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here